KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (2020 - 2025)

Royalty Pharma (RPRX) has disclosed Shares Outstanding for 6 consecutive years, with $411.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 822850.0% to $411.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $411.5 million through Dec 2025, up 822850.0% year-over-year, with the annual reading at $411.5 million for FY2025, 822850.0% up from the prior year.
  • Shares Outstanding hit $148.4 million in Q4 2025 for Royalty Pharma, up from $50000.0 in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $451.0 million in Q1 2024 to a low of $50000.0 in Q1 2021.
  • Historically, Shares Outstanding has averaged $295.1 million across 5 years, with a median of $404.0 million in 2023.
  • Biggest five-year swings in Shares Outstanding: crashed 99.99% in 2024 and later soared 857954.0% in 2025.
  • Year by year, Shares Outstanding stood at $433.0 million in 2021, then dropped by 14.24% to $371.3 million in 2022, then grew by 20.3% to $446.7 million in 2023, then plummeted by 99.99% to $50000.0 in 2024, then skyrocketed by 822850.0% to $411.5 million in 2025.
  • Business Quant data shows Shares Outstanding for RPRX at $411.5 million in Q4 2025, $429.0 million in Q3 2025, and $150.9 million in Q2 2025.